ORGO News and Press, Organogenesis Holdings Inc. From 09/26/22

CANTON, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, t...

CANTON, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, tod...

Organogenesis ( NASDAQ: ORGO ) said the U.S. Food and Drug Administration (FDA) granted 510k clearance to would healing product PuraPly MZ. The company added that PuraPly MZ uses the properties of its PuraPly technology engineered into a micronized (powdered) form to p...

CANTON, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Organogenesis, a leading regenerative medicine company, today announced it has received U.S. Food and Drug Administration (FDA) 510k Clearance for PuraPly MZ , a brand extension to the PuraPly product portfolio. PuraPly MZ leverages the i...

Shares of Organogenesis Holdings (NASDAQ: ORGO) fell by 19.6% as of 2:45 p.m. ET on Wednesday after the wound care company reported worse-than-anticipated Q2 earnings and also slashed its guidance for the rest of 2022. Its net revenue for the quarter was $121.4 million, a decline of...

Image source: The Motley Fool. Organogenesis Holdings Inc. (NASDAQ: ORGO) Q2 2022 Earnings Call Aug 09, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Organogenesis Holdings Inc. (ORGO) Q2 2022 Earnings Call Transc...

Organogenesis Holdings Inc. (ORGO) Q2 2022 Earnings Conference Call August 9, 2022 5:00 PM ET Company Participants Gary Gillheeney - President and Chief Executive Officer Dave Francisco - Chief Financial Officer Conference Call Participants Steve Lichtman...

Organogenesis Holdings press release ( NASDAQ: ORGO ): Q2 GAAP EPS of $0.07. Revenue of $121.4M (-1.5% Y/Y). Adjusted EBITDA of $18.6M for the second quarter of 2022, compared to Adjusted EBITDA of $25.1M for the second quarter of 2021, a decrease of $6.5M. Fisca...

CANTON, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, to...

CANTON, Mass., June 30, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, to...